|
1
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cidon EU: Systemic treatment of
hepatocellular carcinoma: Past, present and future. World J
Hepatol. 9:797–807. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hollebecque A, Malka D, Ferté C, Ducreux M
and Boige V: Systemic treatment of advanced hepatocellular
carcinoma: From disillusions to new horizons. Eur J Cancer.
51:327–339. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hsueh KC, Lee TY, Kor CT, Chen TM, Chang
TM, Yang SF and Hsieh CB: The role of liver transplantation or
resection for patients with early hepatocellular carcinoma. Tumour
Biol. 37:4193–4201. 2016. View Article : Google Scholar
|
|
5
|
Colagrande S, Regini F, Taliani GG, Nardi
C and Inghilesi AL: Advanced hepatocellular carcinoma and
sorafenib: Diagnosis, indications, clinical and radiological
follow-up. World J Hepatol. 7:1041–1053. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chow AK, Ng L, Lam CS, Wong SK, Wan TM,
Cheng NS, Yau TC, Poon RT and Pang RW: The Enhanced metastatic
potential of hepatocellular carcinoma (HCC) cells with sorafenib
resistance. PLoS One. 8:e786752013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu B, Cao Y, Jiang H and Mao A: Autophagy
facilitates the sorafenib resistance of hepatocellular carcinoma
cells. West Indian Med J. 62:698–700. 2013.
|
|
8
|
Ruiz de Galarreta M, Bresnahan E,
Molina-Sánchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela
V, Casanova-Acebes M, Dhainaut M, et al: β-catenin activation
promotes immune escape and resistance to anti-PD-1 therapy in
hepatocellular carcinoma. Cancer Discov. 9:1124–1141. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang G, Lu X and Yuan L: LncRNA: A link
between RNA and cancer. Biochim Biophys Acta. 1839:1097–1109. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fatica A and Bozzoni I: Long non-coding
RNAs: New players in cell differentiation and development. Nat Rev
Genet. 15:7–21. 2014. View
Article : Google Scholar
|
|
11
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wapinski O and Chang HY: Long noncoding
RNAs and human disease. Trends Cell Biol. 21:354–361. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang S, Ma H, Zhang D, Xie S, Wang W, Li
Q, Lin Z and Wang Y: LncRNA KCNQ1OT1 regulates proliferation and
cisplatin resistance in tongue cancer via miR-211-5p mediated
Ezrin/Fak/Src signaling. Cell Death Dis. 9:7422018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ren K, Xu R, Huang J, Zhao J and Shi W:
Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance
to paclitaxel in lung adenocarcinoma. Cancer Chemother Pharmacol.
80:243–250. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang P, Ning S, Zhang Y, Li R, Ye J, Zhao
Z, Zhi H, Wang T, Guo Z and Li X: Identification of
lncRNA-associated competing triplets reveals global patterns and
prognostic markers for cancer. Nucleic Acids Res. 43:3478–3489.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gu S, Jin L, Zhang F, Sarnow P and Kay MA:
Biological basis for restriction of microRNA targets to the 3′
untranslated region in mammalian mRNAs. Nat Struct Mol Biol.
16:144–150. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang M, Xie X, Song X, Gu S, Chang X, Su
T, Liang B and Huang D: MiR-506 suppresses colorectal cancer
development by inhibiting orphan nuclear receptor NR4A1 expression.
J Cancer. 10:3560–3570. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R,
Yang XM, Li J, Zhang YL, Wang YH, Ma MZ, et al: miR-506 acts as a
tumor suppressor by directly targeting the hedgehog pathway
transcription factor Gli3 in human cervical cancer. Oncogene.
34:717–725. 2015. View Article : Google Scholar
|
|
19
|
Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y,
Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K,
et al: MiR-506 inhibits multiple targets in the
epithelial-to-mesenchymal transition network and is associated with
good prognosis in epithelial ovarian cancer. J Pathol. 235:25–36.
2015. View Article : Google Scholar
|
|
20
|
Zhou H, Lin C, Zhang Y, Zhang X, Zhang C,
Zhang P, Xie X and Ren Z: miR-506 enhances the sensitivity of human
colorectal cancer cells to oxaliplatin by suppressing MDR 1/P-gp
expression. Cell Prolif. 50:e123412017. View Article : Google Scholar
|
|
21
|
Wang Z, Dai J, Yan J, Zhang Y and Yin Z:
Targeting EZH 2 as a novel therapeutic strategy for
sorafenib-resistant thyroid carcinoma. J Cell Mol Med.
23:4770–4778. 2019.PubMed/NCBI
|
|
22
|
Svoronos AA, Engelman DM and Slack FJ:
OncomiR or tumor suppressor? The duplicity of microRNAs in cancer.
Cancer Res. 76:3666–3670. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Topalian SL, Drake CG and Pardoll DM:
Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor
immunity. Curr Opin Immunol. 24:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y and Wang L: miR-34a attenuates
glioma cells progression and chemoresistance via targeting PD-L1.
Biotechnol Lett. 39:1485–1492. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen L, Gibbons DL, Goswami S, Cortez MA,
Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al: Metastasis
is regulated via microRNA-200/ZEB1 axis control of tumour cell
PD-L1 expression and intratumoral immunosuppression. Nat Commun.
5:52412014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
28
|
Igney FH and Krammer PH: Immune escape of
tumors: Apoptosis resistance and tumor counterattack. J Leukoc
Biol. 71:907–920. 2002.PubMed/NCBI
|
|
29
|
Chen QN, Wei CC, Wang ZX and Sun M: Long
non-coding RNAs in anti-cancer drug resistance. Oncotarget.
8:1925–1936. 2017. View Article : Google Scholar :
|
|
30
|
Xian D and Zhao Y: LncRNA KCNQ1OT1
enhanced the methotrexate resistance of colorectal cancer cells by
regulating miR-760/PPP1R1B via the cAMP signalling pathway. J Cell
Mol Med. 23:3808–3823. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu H, Yang L, Li L and Zeng C: Long
non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in
hepatocellular carcinoma through miR-7-5p/ABCC1 axis. Biochem
Biophys Res Commun. 503:2400–2406. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Eccles SA, Box C and Court W: Cell
migration/invasion assays and their application in cancer drug
discovery. Biotechnol Annu Rev. 11:391–421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang D, Chen J, Yang L, Ouyang Q, Li J,
Lao L, Zhao J, Liu J, Lu Y, Xing Y, et al: NKILA lncRNA promotes
tumor immune evasion by sensitizing T cells to activation-induced
cell death. Nat Immunol. 19:1112–1125. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ghanem I, Riveiro ME, Paradis V, Faivre S,
de Parga PM and Raymond E: Insights on the CXCL12-CXCR4 axis in
hepatocellular carcinoma carcinogenesis. Am J Transl Res.
6:340–352. 2014.PubMed/NCBI
|
|
36
|
Li KK and Adams DH: Antitumor CD8+ T cells
in hepatocellular carcinoma: Present but exhausted. Hepatology.
59:1232–1234. 2014. View Article : Google Scholar
|
|
37
|
Barrera L, Montes-Servín E, Barrera A,
Ramírez-Tirado LA, Salinas-Parra F, Bañales-Méndez JL,
Sandoval-Ríos M and Arrieta Ó: Cytokine profile determined by
data-mining analysis set into clusters of non-small-cell lung
cancer patients according to prognosis. Ann Oncol. 26:428–435.
2015. View Article : Google Scholar
|
|
38
|
Garris CS, Arlauckas SP, Kohler RH, Trefny
MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M,
Gungabeesoon J, et al: Successful anti-PD-1 cancer immunotherapy
requires T cell-dendritic cell crosstalk involving the cytokines
IFN-γ and IL-12. Immunity. 49:1148–1161. 2018. View Article : Google Scholar
|
|
39
|
Bishop JL, Sio A, Angeles A, Roberts ME,
Azad AA, Chi KN and Zoubeidi A: PD-L1 is highly expressed in
Enzalutamide resistant prostate cancer. Oncotarget. 6:234–242.
2015. View Article : Google Scholar :
|
|
40
|
Liu J, Liu Y, Meng L, Liu K and Ji B:
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib
in human hepatocellular carcinoma. Oncol Rep. 38:899–907. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. . N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
